Please ensure Javascript is enabled for purposes of website accessibility

AbbVie's Humira on Steroids (Literally) Treats Rheumatoid Arthritis Better Than the Original

By Brian Orelli, PhD – Jun 10, 2020 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

That's the finding of a clinical trial of ABBV-3373, a new type of antibody-drug conjugate.

AbbVie (ABBV -5.96%) has a solution for the loss of patent protection on its blockbuster drug Humira: ABBV-3373, a souped-up version of the monoclonal antibody that's quite literally Humira on steroids; it's Humira, an antibody that targets tumor necrosis factor (TNF), connected to a glucocorticoid receptor modulator (GRM) steroid.

In a phase 2a clinical trial, ABBV-3373 reduced the Disease Activity Score 28 C-Reactive Protein (DAS28-CRP) -- a measurement of the severity of rheumatoid arthritis disease -- by 2.65 points, compared to a decline of 2.13 points for patients who were given Humira in other clinical trials. The phase 2a study also had some patients on Humira, and when data from those patients was combined with the historical Humira data, Abbvie calculated that there was a 90% chance that ABBV-3373 was associated with a greater improvement in DAS28-CRP than Humira.

Person holding their swollen hands

Image source: Getty Images.

Antibody-drug conjugates have been used for decades to treat cancer by using an antibody to target a toxic payload to tumor cells. But AbbVie is using the technology to target a molecule -- the GRM steroid that is anti-inflammatory -- to activated immune cells while still blocking the pro-inflammatory TNF protein. By specifically targeting activated immune cells, the drugmaker hopes to dampen the systemic side effects seen with glucocorticoid steroids.

A few other companies are developing antibody-drug conjugates where the additions aren't the traditional toxic payload. Privately held Bolt Biotherapeutics and Silverback Therapeutics, for instance, are using antibodies to target tumor cells and attaching molecules that can stimulate immune cells to attack the cancerous ones. And Avidity Biosciences, which has filed to go public under the ticker RNA, is attaching oligonucleotides to antibodies in order to target them to specific cells in the body.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
$134.21 (-5.96%) $-8.51

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.